Alumis is a biotechnology company focused on developing treatments for autoimmune disease, and their goal is to create therapies that are more precise than currently available autoimmune or immune-mediated disease treatments. Alumis was founded in 2021 and is headquartered in San Francisco, CA. Through its data analytics platform, Alumis seeks to enable researchers to match the right patients to targets, molecules, and combinations so they can create the best possible outcomes.
Date | Funding Round | Funding Raised | Price per Share | Last Known Valuation |
---|---|---|---|---|
3/6/2024 | Series C and C-1 |
$259MM raised | $XXX.XX | $XXX.XX |
5/8/2023 | Series B-2 and B-2A |
$98.89MM raised | $XXX.XX | $XXX.XX |
1/6/2022 | Series B |
$201MM raised | $XXX.XX | $XXX.XX |
5/5/2021 | Series A and B-1 |
$69.04MM raised | $XXX.XX | $XXX.XX |
1/29/2021 | Series Seed |
$10.5MM raised | $XXX.XX | $XXX.XX |